ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009
. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which will arise. In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related biology technology :1
. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast2
. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 20083
. Cambrex Appoints Steven M. Klosk as President and CEO4
. Cambrex Reports Third Quarter 2008 Results5
. Cambrex Receives Notice Regarding NYSE Listing6
. Cambrex Reports First Quarter 2009 Results7
. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award8
. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound9
. QMed, Inc. Reports July Medicare SNP Enrollments10
. Phlo Affiliate Reports Expanded Coverage to Oregon Border11
. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results